According to new research from the Stowers Institute for Medical Research, hematopoietic stem cells [stem cells that produce blood] are directly regulated by megakaryocytes, the blood cells responsible for healing wounds. The researchers found that megakaryotes produce two growth factors; one that signals for hematopoietic stem cells to proliferate, and one that keeps them in an inactive state. This relationship controls the amount of blood being produced in the body.
A research team, led by Dr. Eric Darling of Brown University, has found a potential source of stem cells to protect children with acute lymphoblastic leukemia against the adverse effects of the chemotherapy drug methotrexate (MTX). Adipose-derived stem cells, which appear to be impervious to the bone-degenerative side effects of MTX, may allow children to undergo the chemotherapy treatment and then regain the lost bone tissue afterwards.
Gamida Cell, a leading adult stem cell therapeutics company has completed enrollment for a Phase I/II trial for hematological malignancies utilizing their NiCord treatment. The treatment is a potential cure for blood cancers, sickle cell disease, thalassemia, severe autoimmune diseases and metabolic diseases. This trial is but one example of the increasing number of stem cell treatments moving out of the lab and entering the clinical testing phase.